Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CCR8 | P51685 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153621 | 1.00 | KDM4E (0.47) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL19154409 | 1.00 | KDM4E (0.47) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL19153254 | 1.00 | KDM4E (0.47) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL20958747 | 0.83 | FURIN (0.49) | KDM4ELMNAPKMPIM1PIM3 | |
| SCHEMBL19153754 | 0.82 | KDM4E (0.55) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL19154311 | 0.81 | KDM4E (0.44) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL19153860 | 0.81 | KDM4E (0.44) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL19153259 | 0.79 | KDM4E (0.44) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL19128267 | 0.72 | CHRNB2 (0.46) | KDM4ESMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL13052130 | 0.71 | KDM4E (0.72) | KDM4ESMN1; SMN2RAB9ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787433-B2 | Pyridazine derivatives as EAAT2 activators | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787433-B2 | Pyridazine derivatives as EAAT2 activators | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190040040-A1 | PYRIDAZINE DERIVATIVES AS EAAT2 ACTIVATORS | OHIO STATE UNIVERSITY | 2019-02-07 | — | — | US | disclosed |
| US-20190040040-A1 | PYRIDAZINE DERIVATIVES AS EAAT2 ACTIVATORS | OHIO STATE UNIVERSITY | 2019-02-07 | — | — | US | disclosed |
| WO-2017123991-A1 | PYRIDAZINE DERIVATIVES AS EAAT2 ACTIVATORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787433-B2 | Pyridazine derivatives as EAAT2 activators | SLC1A2, SLC1A1, SLC1A3 | KDM4E 3976/4885SMN1; SMN2 2258/4885RAB9A 1992/4885 |
| US-20190040040-A1 | PYRIDAZINE DERIVATIVES AS EAAT2 ACTIVATORS | SLC1A2, SLC1A1, SLC1A3 | KDM4E 3841/4885SMN1; SMN2 1315/4885RAB9A 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.